0000950170-24-016712.txt : 20240216 0000950170-24-016712.hdr.sgml : 20240216 20240216214816 ACCESSION NUMBER: 0000950170-24-016712 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240214 FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DesRosier Thomas CENTRAL INDEX KEY: 0001435744 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 24650418 MAIL ADDRESS: STREET 1: 65 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 4 1 ownership.xml 4 X0508 4 2024-02-14 0001609809 Seres Therapeutics, Inc. MCRB 0001435744 DesRosier Thomas C/O SERES THERAPEUTICS, INC. 101 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 false true false false Chief Legal Officer and EVP true Common Stock 2024-02-15 4 M false 10625 A 124516 D Common Stock 2024-02-16 4 S false 3939 1.08 D 120577 D Stock Option (Right to Buy) 1.10 2024-02-14 4 A false 213750 0 A 2034-02-13 Common Stock 213750 213750 D Stock Option (Right to Buy) 1.10 2024-02-14 4 A false 287905 0 A 2034-02-13 Common Stock 287905 287905 D Restricted Stock Units 2024-02-14 4 A false 35625 0 A Common Stock 35625 35625 D Restricted Stock Units 2024-02-15 4 M false 10625 0 D Common Stock 10625 31875 D Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter. The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively. The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. /s/ Thomas J. DesRosier 2024-02-16